Can a Double-Targeted cell therapy outsmart Cancer's hideouts?

NCT ID NCT05477927

Recruiting now Disease control Sponsor: Sichuan University Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests a new type of cell therapy for people with solid tumors that have spread to the lining of the chest, abdomen, or brain. The treatment uses a patient's own immune cells, engineered to recognize and attack cancer cells through two different targets. The goal is to see if this approach is safe and whether it can shrink or control the cancer in these difficult-to-treat areas.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dual-targeting VEGFR1/PD-L1 CAR-T cells
What this could lead to: If successful, this approach could offer a new treatment option for patients with hard-to-treat cancer spread in the body cavities or around the brain, potentially improving outcomes where current options are limited.
What could go wrong: This is an early-phase trial, so the treatment may not be safe or effective. Possible risks include severe immune reactions or side effects from the engineered cells. The results may not generalize to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Meningeal Carcinomatosis neoplastic meningitis peritoneal carcinomatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEPTOMENINGEAL METASTASES MALIGNANT ASCITES MALIGNANT PERITONEAL EFFUSION SEROUS CAVITY METASTATISES

Contacts and locations

Locations

West China Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.